Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a ...

So far, only one drug has been approved by the FDA: gemtuzumab ozogamicin (Mylotarg; Pfizer), a humanized mAb specific for CD33, conjugated to the cytotoxic drug calicheamicin, was approved in ...

The world’s first approved antibody-drug conjugate, where a targeted antibody delivers a toxic payload to cancer cells, Mylotarg (gemtuzumab ozogamicin) was first approved in 2000. But it was ...

To date, the US Food and Drug Administration has only approved four anticancer ADCs since Wyeth’s Mylotarg came to market almost 20 years ago. The travails of the ADC sector can be partly ...

(NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.

An example is the first-ever “magic bullet” drug, or antibody-drug conjugate: gemtuzumab ozogamicin (Mylotarg). The leukemia drug was based on Dr. Bernstein’s fundamental research on blood cell ...

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment ...